Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Regdanvimab showed no clear difference in adverse events: all grades compared with placebo (low certainty).
1 finding from 1 review
Adverse events: all grades · non‐hospitalised individuals with COVID‐19
Bamlanivimab showed no clear difference in adverse events: all grades compared with placebo (low certainty).
1 finding from 1 review
Adverse events: all grades · individuals with moderate to severe disease
It is very uncertain whether summary of Findings Table ‐ Vitamin D changes adverse events (any grade) compared with placebo or standard care alone (very low certainty).
1 finding from 1 review
Adverse events (narrative) · patients with fibromyalgia
1 finding from 1 review
no estimate extracted
2008 participants
GRADE not reported
Adverse events (narrative) · patients with fibromyalgia
1 finding from 1 review
Adverse events: all grades · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Adverse events: all grades · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
1 finding from 1 review
Grades 3 and 4 adverse events · individuals with moderate to severe disease
1 finding from 1 review
Grades 3 and 4 adverse events · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in grades 3 and 4 adverse events compared with placebo or standard care alone (low certainty).
1 finding from 1 review
Adverse events ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ not measured · individuals with sickle cell disease and a leg ulcer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ not reported · individuals with sickle cell disease and a leg ulcer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ total · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in serious adverse events ‐ total compared with placebo or standard care alone (moderate certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Sotrovimab may leads to lower adverse events: grades 3 and 4 compared with placebo (low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Regdanvimab showed no clear difference in adverse events: grades 3 and 4 compared with placebo (low certainty).
1 finding from 1 review
Total adverse events · children aged 5 to 11 years with ASD
D‐cycloserine showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
Serious adverse events by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in serious adverse events by day 30 compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any adverse events Up to 3 months · patients with depression
Music therapy plus treatment as usual (TAU) showed no clear difference in any adverse events Up to 3 months compared with TAU (low certainty).
1 finding from 1 review